XTX Topco
TRDA icon

XTX Topco’s Entrada Therapeutics TRDA Stock Holding History

XTX Topco’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$702K Sell
95,337
-34,225
-26% -$328K 0.01% 2112
2026
Q1 		$1.64M Buy
129,562
+11,894
+10% +$136K 0.03% 993
2025
Q4 		$1.21M Buy
117,668
+24,589
+26% +$207K 0.03% 891
2025
Q3 		$540K Buy
+93,079
New +$545K 0.03% 1013
2024
Q4 		– Sell
-39,670
Closed -$634K – 2943
2024
Q3 		$634K Buy
+39,670
New +$625K 0.05% 655

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

XTX Topco's TRDA Position: Q2 2026 in Review

XTX Topco reduced its Entrada Therapeutics (TRDA) stake by 26% in Q2 2026, selling an estimated $328K and leaving 95,337 shares worth $702K. The position accounts for 0.01% of the portfolio, ranked #2112.

XTX Topco first reported a position in TRDA in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.64M in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • XTX Topco held 95,337 shares of Entrada Therapeutics worth $702K as of Q2 2026.
  • XTX Topco sold 34,225 Entrada Therapeutics shares in Q2 2026, an estimated $328K.
  • Entrada Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2112 holding.
  • XTX Topco first reported a position in Entrada Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • XTX Topco's Entrada Therapeutics position peaked at $1.64M in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.